These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 31570385)

  • 1. Hepatitis C Virus Epidemiology and the Impact of Interferon-Free Hepatitis C Virus Therapy.
    Lazarus JV; Roel E; Elsharkawy AM
    Cold Spring Harb Perspect Med; 2020 Mar; 10(3):. PubMed ID: 31570385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes to the national strategies, plans and guidelines for the treatment of hepatitis C in people who inject drugs between 2013 and 2016: a cross-sectional survey of 34 European countries.
    Maticic M; Zorman JV; Gregorcic S; Schatz E; Lazarus JV
    Harm Reduct J; 2019 May; 16(1):32. PubMed ID: 31072401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The civil society monitoring of hepatitis C response related to the WHO 2030 elimination goals in 35 European countries.
    Maticic M; Pirnat Z; Leicht A; Zimmermann R; Windelinck T; Jauffret-Roustide M; Duffell E; Tammi T; Schatz E
    Harm Reduct J; 2020 Nov; 17(1):89. PubMed ID: 33213481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment advocate tactics to expand access to antiviral therapy for HIV and viral hepatitis C in low- to high-income settings: making sure no one is left behind.
    Grillon C; Krishtel PR; Mellouk O; Basenko A; Freeman J; Mendão L; Andrieux-Meyer I; Morin S
    J Int AIDS Soc; 2018 Apr; 21 Suppl 2(Suppl Suppl 2):e25060. PubMed ID: 29633580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ten priorities for expanding access to HCV treatment for people who inject drugs in low- and middle-income countries.
    Ford N; Wiktor S; Kaplan K; Andrieux-Meyer I; Hill A; Radhakrishnan P; Londeix P; Forette C; Momenghalibaf A; Verster A; Swan T
    Int J Drug Policy; 2015 Nov; 26(11):1088-93. PubMed ID: 26074094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elimination of HCV in Russia: Barriers and Perspective.
    Isakov V; Nikityuk D
    Viruses; 2022 Apr; 14(4):. PubMed ID: 35458520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis C: global epidemiology and strategies for control.
    Lanini S; Easterbrook PJ; Zumla A; Ippolito G
    Clin Microbiol Infect; 2016 Oct; 22(10):833-838. PubMed ID: 27521803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progress Toward Hepatitis C Virus Elimination: Therapy and Implementation.
    Martinello M; Bajis S; Dore GJ
    Gastroenterol Clin North Am; 2020 Jun; 49(2):253-277. PubMed ID: 32389362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. "Everybody living with a chronic disease is entitled to be cured": Challenges and opportunities in scaling up access to direct-acting antiviral hepatitis C virus treatment among people who inject drugs.
    Goodyear T; Ti L; Carrieri P; Small W; Knight R
    Int J Drug Policy; 2020 Jul; 81():102766. PubMed ID: 32416525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Variation in hepatitis C virus treatment uptake between Canadian centres in the era of direct-acting antivirals.
    Nitulescu R; Young J; Saeed S; Cooper C; Cox J; Martel-Laferriere V; Hull M; Walmsley S; Tyndall M; Wong A; Klein MB;
    Int J Drug Policy; 2019 Mar; 65():41-49. PubMed ID: 30594080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The removal of DAA restrictions in Europe - One step closer to eliminating HCV as a major public health threat.
    Marshall AD; Pawlotsky JM; Lazarus JV; Aghemo A; Dore GJ; Grebely J
    J Hepatol; 2018 Nov; 69(5):1188-1196. PubMed ID: 29959953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Global reporting of progress towards elimination of hepatitis B and hepatitis C.
    Cui F; Blach S; Manzengo Mingiedi C; Gonzalez MA; Sabry Alaama A; Mozalevskis A; Séguy N; Rewari BB; Chan PL; Le LV; Doherty M; Luhmann N; Easterbrook P; Dirac M; de Martel C; Nayagam S; Hallett TB; Vickerman P; Razavi H; Lesi O; Low-Beer D
    Lancet Gastroenterol Hepatol; 2023 Apr; 8(4):332-342. PubMed ID: 36764320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis C, a global issue: access to care and new therapeutic and preventive approaches in resource-constrained areas.
    Lemoine M; Thursz M
    Semin Liver Dis; 2014 Feb; 34(1):89-97. PubMed ID: 24782262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elimination of hepatitis C virus infection among people who use drugs: Ensuring equitable access to prevention, treatment, and care for all.
    Grebely J; Hajarizadeh B; Lazarus JV; Bruneau J; Treloar C;
    Int J Drug Policy; 2019 Oct; 72():1-10. PubMed ID: 31345644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between rapid utilisation of direct hepatitis C antivirals and decline in the prevalence of viremia among people who inject drugs in Australia.
    Iversen J; Dore GJ; Catlett B; Cunningham P; Grebely J; Maher L
    J Hepatol; 2019 Jan; 70(1):33-39. PubMed ID: 30367897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Securing sustainable funding for viral hepatitis elimination plans.
    Hatzakis A; Lazarus JV; Cholongitas E; Baptista-Leite R; Boucher C; Busoi CS; Deuffic-Burban S; Chhatwal J; Esmat G; Hutchinson S; Malliori MM; Maticic M; Mozalevskis A; Negro F; Papandreou GA; Papatheodoridis GV; Peck-Radosavljevic M; Razavi H; Reic T; Schatz E; Tozun N; Younossi Z; Manns MP
    Liver Int; 2020 Feb; 40(2):260-270. PubMed ID: 31808281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eliminating Structural Barriers: The Impact of Unrestricted Access on Hepatitis C Treatment Uptake Among People Living With Human Immunodeficiency Virus.
    Saeed S; Strumpf E; Moodie EEM; Wong L; Cox J; Walmsley S; Tyndall M; Cooper C; Conway B; Hull M; Martel-Laferriere V; Gill J; Wong A; Vachon ML; Klein MB;
    Clin Infect Dis; 2020 Jul; 71(2):363-371. PubMed ID: 31504327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. French hepatitis C care cascade: substantial impact of direct-acting antivirals, but the road to elimination is still long.
    Brouard C; Pillonel J; Boussac M; de Lédinghen V; Rachas A; Silvain C; Lydié N; Chevaliez S; Pioche C; Durand J; Lot F; Delarocque-Astagneau E
    BMC Infect Dis; 2020 Oct; 20(1):759. PubMed ID: 33059617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Impact of Enhanced Screening and Treatment on Hepatitis C in the United States.
    Durham DP; Skrip LA; Bruce RD; Vilarinho S; Elbasha EH; Galvani AP; Townsend JP
    Clin Infect Dis; 2016 Feb; 62(3):298-304. PubMed ID: 26628566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retrieval of chronic hepatitis C patients. A manifesto for action to eliminate hepatitis C in the Netherlands: the CELINE project.
    van Dijk M; Kracht PAM; Arends JE; Blokzijl H; Burger DM; van Erpecum KJ; van Hoek B; de Knegt RJ; Posthouwer D; Ramsoekh D; Rijnders BJA; Schinkel J; Willemse SB; van der Valk M; Drenth JPH; Behalf Of The HepNed Study Group O
    Neth J Med; 2019 May; 77(4):131-138. PubMed ID: 31502544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.